RTSL
Rapid Therapeutic Science Laboratories, Inc.0.0020
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
37.97KP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
8-K
Auditor, directors resign
TPS Thayer resigned as Rapid Therapeutic's auditor effective November 28, 2023, for business reasons, just four months after engagement; no replacement firm engaged yet. Independent directors Dr. Henry A. Punzi and J. Scott Suggs resigned effective December 1, leaving zero independents. Governance gaps widen.
8-K
Amends $2.35M debentures, adds warrants
Rapid Therapeutic Science Laboratories amended past-due convertible debentures totaling $2.35M with its key investor on August 22, 2023, extending maturity to December 31 or earlier upon qualified offering or exchange listing. Conversion price dropped to 65% of the lowest 10-day VWAP; existing warrants slashed to $0.01 exercise price through 2028, plus 5M new warrants at $0.01 expiring 2029. Parties swapped full releases. Dilution risk looms large.
10-Q
Q2 FY2023 results
Rapid Therapeutic swung to a $46K net income for Q2 ended June 30, 2023, from a $37K loss y/y, driven by $128K gain on derivative valuations and $83K employer tax refund, yet posted a $104K operating loss versus $128K prior (derived). QTD operating expenses dropped 19% y/y to $104K on lower uplisting costs. YTD net income hit $238K from $1.6M loss y/y, with cash at $2K but $4.1M working capital deficit and $3.4M notes payable mostly current. Debt conversions added 668K shares. Convertible debentures loom past due. FDA approval delays pose key risk.
8-K
Auditor switch, no issues
Rapid Therapeutic Science Laboratories switched auditors on July 12, 2023, as PWR CPA resigned for business reasons and TPS Thayer stepped in immediately. No disagreements, adverse opinions, or reportable events marred PWR's audits through mid-2023. Clean handover. Investors note the routine shift lacks red flags.
10-Q
Q1 FY2023 results
Rapid Therapeutic Science Laboratories swung to a $191k net income for Q1 ended March 31, 2023, from a $1.6M loss y/y, thanks to a $401k gain on derivative valuations that offset $98k operating expenses, down sharply from $789k y/y. No revenue yet, as sales remain suspended pending FDA IND filing. Cash climbed to $18k q/q via $59k financing inflows, yet total notes payable held at $3.4M, mostly past due convertibles, with stockholders' deficit shrinking to $2.8M. Operating cash burned $42k. Debt overhang looms large.
CBDL
CBD Life Sciences Inc.
0.00+0.00
CSLMF
CSLM Acquisition Corp.
3.14+0.54
RAPH
RAPHAEL PHARMACEUTICAL INC
1.40+0.00
RAPT
RAPT Therapeutics, Inc.
34.03+0.81
RMSL
RemSleep Holdings, Inc.
0.00+0.00
RRACF
Rigel Resource Acquisition Corp
11.89+0.00
RTAC
Renatus Tactical Acquisition Co
10.59+0.07
TCRI
TECHCOM INC.
0.17-0.00
TDAC
Translational Development Acqui
10.42+0.00
TNBI
Tanke Biosciences Corp.
0.03+0.00